Market Cap 84.47M
Revenue (ttm) 0.00
Net Income (ttm) -41.52M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 723,900
Avg Vol 1,535,446
Day's Range N/A - N/A
Shares Out 53.46M
Stochastic %K 53%
Beta 0.96
Analysts Sell
Price Target $3.33

Company Profile

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collabora...

Industry: Biotechnology
Sector: Healthcare
Phone: 514-336-0444
Address:
1111 Dr. Frederik-Philips Boulevard, Suite 420, Montreal, Canada
NVDAMillionaire
NVDAMillionaire Jul. 28 at 8:35 PM
$MIST Brilliant piece that captures MIST's situation perfectly. So if you want to update your understanding of MIST or get to know MIST better, this is essential reading. https://beyondspx.com/article/milestone-pharmaceuticals-awaiting-the-cardamyst-verdict-nasdaq-mist
0 · Reply
Diverstj981
Diverstj981 Jul. 28 at 5:04 PM
$MIST Investors have obviously lost confidence in the management team. This company is a pure amateur hour shit-show. It's sad because there's so much potential. These clowns just fail repeatedly to execute.
0 · Reply
Bearssuckbutt
Bearssuckbutt Jul. 28 at 5:03 PM
$MIST $10 after approval! i have seen $OCGN $SMMT got from single digits to double digits in matter of weeks! buy buy buy!!
1 · Reply
Rroper
Rroper Jul. 28 at 3:42 PM
$MIST Price down shorts. I want this cheaper. Paytience
0 · Reply
Bearssuckbutt
Bearssuckbutt Jul. 28 at 3:23 PM
$MIST maybe we need a pump like $CELC and $CEAD
0 · Reply
jjangles123
jjangles123 Jul. 28 at 11:16 AM
$MIST 1.75$ end of this week
1 · Reply
Bearssuckbutt
Bearssuckbutt Jul. 27 at 6:15 PM
$MIST some facts to grind on- -More than 454,000 hospitalizations with AFib as the primary diagnosis happen each year with over 158k deaths - estimated 2.7 to 6.1 million people in the US are affected by AFIB -estimated cost to healthcare at $26 billion -If Cardamyst can address symptoms and reduce the burden to health care, this will be in fact a default therapy to treat the symptoms and reduce ER visits. - Come Dec and anticipted PDUFA approval, this will be most anticipated therapy on the market! wont be surprised if it gets scooped up $15+ by $BMY $OCGN $SMMT $DRUG
0 · Reply
Bearssuckbutt
Bearssuckbutt Jul. 27 at 5:32 PM
$MIST some facts to grind on- -More than 454,000 hospitalizations with AFib as the primary diagnosis happen each year with over 158k deaths - estimated 2.7 to 6.1 million people in the US are affected by AFIB -estimated cost to healthcare at $26 billion -If Cardamyst can address symptoms and reduce the burden to health care, this will be in fact a default therapy to treat the symptoms and reduce ER visits. - Come Dec and anticipted PDUFA approval, this will be most anticipated therapy on the market! wont be surprised if it gets scooped up $15+ by $BMY do your own research $SRPT $NVAX $VERU
0 · Reply
chezki
chezki Jul. 27 at 3:32 PM
$MIST LIKE THIS!
0 · Reply
chezki
chezki Jul. 27 at 3:29 PM
$MIST DO NOT GET TIRED!! LETS HOLD IT TOGETHER!
0 · Reply
Latest News on MIST
Milestone Pharmaceuticals Announces Proposed Public Offering

Jul 11, 2025, 6:01 AM EDT - 17 days ago

Milestone Pharmaceuticals Announces Proposed Public Offering


FDA Issues Complete Response Letter for Etripamil for PSVT

Mar 28, 2025, 7:00 AM EDT - 4 months ago

FDA Issues Complete Response Letter for Etripamil for PSVT


Milestone Pharmaceuticals: Worthy Of A Dart Throw

May 22, 2023, 2:37 PM EDT - 2 years ago

Milestone Pharmaceuticals: Worthy Of A Dart Throw


NVDAMillionaire
NVDAMillionaire Jul. 28 at 8:35 PM
$MIST Brilliant piece that captures MIST's situation perfectly. So if you want to update your understanding of MIST or get to know MIST better, this is essential reading. https://beyondspx.com/article/milestone-pharmaceuticals-awaiting-the-cardamyst-verdict-nasdaq-mist
0 · Reply
Diverstj981
Diverstj981 Jul. 28 at 5:04 PM
$MIST Investors have obviously lost confidence in the management team. This company is a pure amateur hour shit-show. It's sad because there's so much potential. These clowns just fail repeatedly to execute.
0 · Reply
Bearssuckbutt
Bearssuckbutt Jul. 28 at 5:03 PM
$MIST $10 after approval! i have seen $OCGN $SMMT got from single digits to double digits in matter of weeks! buy buy buy!!
1 · Reply
Rroper
Rroper Jul. 28 at 3:42 PM
$MIST Price down shorts. I want this cheaper. Paytience
0 · Reply
Bearssuckbutt
Bearssuckbutt Jul. 28 at 3:23 PM
$MIST maybe we need a pump like $CELC and $CEAD
0 · Reply
jjangles123
jjangles123 Jul. 28 at 11:16 AM
$MIST 1.75$ end of this week
1 · Reply
Bearssuckbutt
Bearssuckbutt Jul. 27 at 6:15 PM
$MIST some facts to grind on- -More than 454,000 hospitalizations with AFib as the primary diagnosis happen each year with over 158k deaths - estimated 2.7 to 6.1 million people in the US are affected by AFIB -estimated cost to healthcare at $26 billion -If Cardamyst can address symptoms and reduce the burden to health care, this will be in fact a default therapy to treat the symptoms and reduce ER visits. - Come Dec and anticipted PDUFA approval, this will be most anticipated therapy on the market! wont be surprised if it gets scooped up $15+ by $BMY $OCGN $SMMT $DRUG
0 · Reply
Bearssuckbutt
Bearssuckbutt Jul. 27 at 5:32 PM
$MIST some facts to grind on- -More than 454,000 hospitalizations with AFib as the primary diagnosis happen each year with over 158k deaths - estimated 2.7 to 6.1 million people in the US are affected by AFIB -estimated cost to healthcare at $26 billion -If Cardamyst can address symptoms and reduce the burden to health care, this will be in fact a default therapy to treat the symptoms and reduce ER visits. - Come Dec and anticipted PDUFA approval, this will be most anticipated therapy on the market! wont be surprised if it gets scooped up $15+ by $BMY do your own research $SRPT $NVAX $VERU
0 · Reply
chezki
chezki Jul. 27 at 3:32 PM
$MIST LIKE THIS!
0 · Reply
chezki
chezki Jul. 27 at 3:29 PM
$MIST DO NOT GET TIRED!! LETS HOLD IT TOGETHER!
0 · Reply
Bearssuckbutt
Bearssuckbutt Jul. 27 at 2:38 AM
$MIST Kind of ironic read an article that AFIB has increased and on the rise since 2021! would that be thanks to $PFE and $MRNA maybe after all Cardamyst will be the answer to that jab! https://www.healthcentral.com/condition/atrial-fibrillation/why-are-afib-rates-on-the-rise
1 · Reply
BinaryLogic
BinaryLogic Jul. 26 at 1:57 AM
2 · Reply
jjangles123
jjangles123 Jul. 25 at 11:33 PM
$MIST I like how I put my case all in one post but my guy had to spread it out. The loudest in the room is also quite often the weakest.
1 · Reply
TheGreedyGrench
TheGreedyGrench Jul. 25 at 10:39 PM
$MIST Dumping after hours. What do the institutions know that retail MIST bag holders do not??
1 · Reply
TheGreedyGrench
TheGreedyGrench Jul. 25 at 10:38 PM
$MIST Would the Grench recommend investing your money into the MIST??? NOPE!
0 · Reply
TheGreedyGrench
TheGreedyGrench Jul. 25 at 10:38 PM
$MIST BEAR Case: 6 Institutional Selling / Insider Activity Major holders like Millennium Management LLC have recently trimmed their positions, reducing institutional ownership slightly potentially signaling waning confidence at the margins
0 · Reply
TheGreedyGrench
TheGreedyGrench Jul. 25 at 10:37 PM
$MIST BEAR Case: 5 this one is my favorite and see this stock going to 0 Valuation & Speculative Profile MIST has no revenue, negative free cash flow, and a very low market cap (~$40 M–$125 M depending on source) This makes it highly speculative, with most upside tied to the success of a single FDA decision
1 · Reply
TheGreedyGrench
TheGreedyGrench Jul. 25 at 10:36 PM
$MIST BEAR Case: 4 Negative Momentum in Technicals Technical analysis shows bearish sentiment: the current price (~$0.75) is below key moving averages (20‑, 50‑, 200‑day), even as momentum indicators like RSI are low but not oversold suggesting limited technical support for a bounce
0 · Reply
TheGreedyGrench
TheGreedyGrench Jul. 25 at 10:36 PM
$MIST BEAR Case: 3 Financial Strain & Cash Burn As of March 31, 2025, cash reserves stand at $56 million, down from $69.7 million at year-end 2024, while net loss for Q1 2025 doubled to –$20.8 million year-over-year The company continues to burn cash, and upcoming milestones (e.g. FDA decision, product launch) hinge on securing further financing, posing execution and liquidity risk
0 · Reply
TheGreedyGrench
TheGreedyGrench Jul. 25 at 10:34 PM
$MIST BEAR Case: 2 MIST announced a proposed public offering (common stock and warrants) in early July 2025. Investors reacted with a ~32% share price drop due to dilution concerns and lack of clarity over pricing and size
0 · Reply
TheGreedyGrench
TheGreedyGrench Jul. 25 at 10:33 PM
$MIST BEAR Case: 1 The FDA issued a Complete Response Letter (CRL) for the lead drug CARDAMYST™ (etripamil) due to Chemistry, Manufacturing, and Controls (CMC) concerns—specifically, issues with nitrosamine impurities and a required inspection of a facility that changed ownership during review These regulatory hurdles delayed the FDA approval timeline by about a year, pushing back a previously expected March 2025 decision and resetting expectations toward December 13, 2025
0 · Reply
jjangles123
jjangles123 Jul. 25 at 9:29 PM
$MIST BULL Case: 1. Resolved CRL, the only issue was CMC/Manufacturing issues, not the efficacy of the safety or efficacy. 2. Institutional Validity, Trail’s Edge recently purchased 9.9% of the OS. 1.50$ range is a good entry. 3. Recent dilution/offering is priced in. Sharp drop from 2.5$ to 1.5$ after the news dropped. So the bad news is over. I believe it’s a climb to PDUFA day in December.
0 · Reply